CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer

58Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We have combined data from case control studies designed to test the hypothesis that the c-160a promotor polymorphism in the gene coding for the cell adhesion molecule E-cadherin (CDH 1) is associated with stomach cancer. A total of 899 individuals (433 patients and 466 controls) were analyzed. The genotype frequencies did not differ significantly between cases and controls, and the genotype-specific risks were not significantly different from unity, with an odds ratio for heterozygotes compared with the common homozygote of 1.3 (95% CI 0.98-1.8) and 1.2 (0.68-2.0) for rare homozygotes compared with common homozygotes. We found no evidence for differences in risk for the intestinal- and diffusetype histopathologic subgroups. © 2002 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Pharoah, P. D. P., Oliveira, C., Machado, J. C., Keller, G., Vogelsang, H., Laux, H., … Huntsman, D. (2002). CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. International Journal of Cancer, 101(2), 196–197. https://doi.org/10.1002/ijc.10590

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free